Compare ELMD & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMD | TGTX |
|---|---|---|
| Founded | 1992 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.9M | 8.5B |
| IPO Year | 2010 | 2008 |
| Metric | ELMD | TGTX |
|---|---|---|
| Price | $27.57 | $58.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $36.00 | ★ $49.80 |
| AVG Volume (30 Days) | 108.3K | ★ 1.6M |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 52.94 | ★ 1746.67 |
| EPS | ★ 1.30 | 0.17 |
| Revenue | ★ $54,716,000.00 | $2,785,000.00 |
| Revenue This Year | $15.59 | $49.08 |
| Revenue Next Year | $11.51 | $26.69 |
| P/E Ratio | ★ $20.77 | $336.24 |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $23.01 | $26.76 |
| 52 Week High | $47.40 | $59.30 |
| Indicator | ELMD | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.73 | 61.27 |
| Support Level | $27.14 | $51.76 |
| Resistance Level | $30.26 | $58.12 |
| Average True Range (ATR) | 0.99 | 2.10 |
| MACD | 0.39 | 0.15 |
| Stochastic Oscillator | 79.41 | 78.74 |
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.